NGNE
NASDAQ HealthcareNeurogene Inc. - Common Stock
Biotechnology
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
�� 市场数据
| 价格 | $27.85 |
|---|---|
| 成交量 | 324,429 |
| 市值 | 434.90M |
| 贝塔系数 | 1.890 |
| RSI（14日） | 72.5 超买 |
| 200日均线 | $21.53 |
| 50日均线 | $20.48 |
| 52周最高 | $37.27 |
| 52周最低 | $11.27 |
| Forward P/E | -5.02 |
| Price / Book | 1.63 |
🎯 投资策略评分
NGNE 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🚀 Moon Shot (90/100) — 此策略 高增长潜力（高贝塔 + 超卖）.
评分最低的策略： 💰 Dividend Daddy (7/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 NGNE in your text
粘贴任何文章、记录或帖子 — 工具将提取 NGNE 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.